No title
Genomics — the sequencing of the human genome and the identification of the genetic mechanisms of development and disease — is driving a restructuring of the global pharmaceutical industry. Many policy initiatives in biomedicine are based on the assumption that strength in genomics research will be translated into economic success, that is, that investments in genomics will be a way to catch up in
